AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 320
- Registration Number
- NCT06020014
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 460
- Registration Number
- NCT06015737
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 280
- Registration Number
- NCT06008093
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT06005493
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
PICAROS - Acalabrutinib RWE on 1L CLL in Spain
- Conditions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 192
- Registration Number
- NCT05999877
- Locations
- 🇪🇸
Research Site, Murcia, Region De Murcia, Spain
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 900
- Registration Number
- NCT05984277
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT05970263
A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria
- Conditions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2575
- Registration Number
- NCT05967806
- Locations
- 🇻🇳
Research Site, Ho Chi Minh City, Vietnam
Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 41
- Registration Number
- NCT05966324
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT05961397
- Locations
- 🇺🇸
American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Inland Empire Clinical Trials, Rialto, California, United States